CMS recently released data identifying the costliest drugs to Medicare in 2015, and Gilead Sciences' hepatitis C treatment Harvoni topped the list.
According to the data, the eight Medicare Part D drugs with the highest total spending each accounted for more than $2 billion in gross Part D spending last year. The five costliest Medicare Part B drugs in 2015 are the same as in 2014, and combined they totaled more than $7 billion in spending, according to CMS.
Here are the 15 drugs that Medicare spent the most on in 2015.
1. Harvoni (hepatitis C treatment) — $7.03 billion
2. Lantus; Lantus Solostar (diabetes) — $4.36 billion
3. Crestor (high cholesterol) — $2.88 billion
4. Advair Diskus (asthma) — $2.27 billion
5. Spiriva (COPD) — $2.19 billion
6. Januvia (diabetes) — $2.13 billion
7. Revlimid (anemia) — $2.08 billion
8. Nexium (gastroesophageal reflux disease) — $2.01 billion
9. Eylea (age-related macular degeneration) — $1.81 billion
10. Lyrica (nerve and muscle pain) — $1.77 billion
11. Humira; Humira Pen (rheumatoid arthritis) — $1.66 billion
12. Abilify (mental/mood disorders) — $1.57 billion
13. Rituxan (cancer) — $1.56 billion
14. Xarelto (blood clots) — $1.52 billion
15. Enbrel (Tumor Necrosis Factor inhibitor) — $1.39 billion
More articles on healthcare finance:
Quorum Health adds 6 more hospitals to sale pipeline
Kindred to close Texas hospital, leaving 92 without jobs
Fitch: ACA repeal would be credit negative for hospitals